Roflumilast

روفلوميلاست

KindAPI
ClassRespiratory anti-inflammatory — selective PDE4 inhibitor
SynonymsB9302-107, APTA-2217, Daliresp, Daxas
Common uses / formsOral tablets 250 / 500 µg (severe COPD with bronchitis); topical cream in dermatology
PropertiesPotent low-dose small molecule; poorly water soluble (BCS Class II/IV behaviour) — dissolution particle-size sensitive; active N-oxide metabolite; low-dose content uniformity critical
Sourcing originsIndia, China, EU
Dominant inbound routeHormuz
Indicative price band$$$$ (> $1000 / kg)
Indicative lead timemedium (50–80 days)
NotesQualify against innovator/CEP specs where public monograph coverage is thin; genotoxic-impurity control and low-dose blend uniformity are key; post-patent Indian generics available
Indicative planning bands for reference/education — not supplier quotes. Sourcing routes reflect the dominant inbound lane to the Arab region.

Open the interactive Data Bank (363 substances) · the full table · Supply Resilience Studio

Share: LinkedIn · X · WhatsApp · Telegram · Email

Cite as: AUPAM Experts' Office, Roflumilast — sourcing profile (API) — AUPAM Data Bank, retrieved 2026-08-31, https://aupameo.org/datasets/databank/a-roflumilast.html